We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intravenous dantrolene in hypermetabolic syndromes: a survey of the U.S. Veterans Health Administration database.
- Authors
Caroff, Stanley N.; Roberts, Christopher B.; Rosenberg, Henry; Tobin, Joseph R.; Watt, Stacey; Mashman, Darlene; Riazi, Sheila; Berkowitz, Rosalind M.
- Abstract
Background: Intravenous dantrolene is often prescribed for hypermetabolic syndromes other than the approved indication of malignant hyperthermia (MH). To clarify the extent of and indications for dantrolene use in conditions other than MH, we sought to document current practices in the frequency, diagnoses, clinical characteristics and outcomes associated with dantrolene treatment in critical care settings. Methods: Inpatients receiving intravenous dantrolene from October 1, 2004 to September 30, 2014 were identified retrospectively in the U.S. Veterans Health Administration national database. Extracted data included; diagnoses of hypermetabolic syndromes; triggering drugs; dantrolene dosages; demographics; vital signs; laboratory values; in-hospital mortality; complications; and lengths of stay. Frequency and mortality of patients who did not receive dantrolene were obtained in selected diagnoses for exploratory comparisons. Results: Dantrolene was administered to 304 inpatients. The most frequent diagnoses associated with dantrolene treatment were neuroleptic malignant syndrome (NMS; N = 108, 35.53%) and sepsis (N = 47, 15.46%), with MH accounting for only 13 (4.28%) cases. Over half the patients had psychiatric comorbidities and received psychotropic drugs before dantrolene treatment. Common clinical findings in patients receiving dantrolene included elevated temperature (mean ± SD; 38.7 ± 1.3 °C), pulse (116.33 ± 22.80/bpm), respirations (27.75 ± 9.58/min), creatine kinase levels (2,859.37 ± 6,646.88 IU/L) and low pO2 (74.93 ± 40.16 mmHg). Respiratory, renal or cardiac failure were common complications. Mortality rates in-hospital were 24.01% overall, 7.69% in MH, 20.37% in NMS and 42.55% in sepsis, compared with mortality rates in larger and possibly less severe groups of unmatched patients with MH (5.26%), NMS (6.66%), or sepsis (41.91%) who did not receive dantrolene. Conclusions: In over 95% of cases, dantrolene administration was associated with diagnoses other than MH in critically-ill patients with hypermetabolic symptoms and medical and psychiatric comorbidities. Exploratory survey data suggested that the efficacy and safety of dantrolene in preventing mortality in hypermetabolic syndromes other than MH remain uncertain. However, randomized and controlled studies using standardized criteria between groups matched for severity are essential to guide practice in using dantrolene.
- Subjects
UNITED States; MENTAL illness drug therapy; AMERICAN veterans; DANTROLENE; DRUG efficacy; INTRAVENOUS therapy; RHABDOMYOLYSIS; PSYCHIATRIC drugs; BODY temperature; RESEARCH methodology; CRITICALLY ill; RETROSPECTIVE studies; ACQUISITION of data; CREATINE kinase; PATIENTS; SEPSIS; MALIGNANT hyperthermia; HOSPITAL mortality; SYMPTOMS; MEDICAL records; DESCRIPTIVE statistics; RESPIRATION; NEUROLEPTIC malignant syndrome; COMORBIDITY
- Publication
BMC Anesthesiology, 2022, Vol 22, Issue 1, p1
- ISSN
1471-2253
- Publication type
Article
- DOI
10.1186/s12871-022-01841-z